GS Group and Goldman Sachs & Co. Report 803,487 Shares in OACCW
Rhea-AI Filing Summary
The Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC report shared beneficial ownership of 803,487 Class A ordinary shares of Oaktree Acquisition Corp. III Life Sciences, representing 4.1% of the class. Both reporting persons indicate zero sole voting and dispositive power and shared voting and dispositive power of 803,487, showing the stake is held jointly rather than under exclusive control by either entity.
The filing states the securities are held in the ordinary course of business and were not acquired to change or influence control. A joint filing agreement is attached and an exhibit clarifies that The Goldman Sachs Group, Inc. is a parent holding company and Goldman Sachs & Co. LLC is a subsidiary broker-dealer and registered investment adviser. The filing is classified as ownership of 5% or less of the class.
Positive
- Disclosure of precise ownership: 803,487 shares disclosed, providing clear transparency
- Joint filing and organizational clarity: Exhibit confirms GS Group is parent and Goldman Sachs & Co. LLC is the subsidiary broker-dealer/adviser
Negative
- None.
Insights
TL;DR: Goldman Sachs entities disclose a passive 4.1% (803,487-share) holding in Oaktree Acquisition Corp. III Life Sciences with shared control.
The disclosure is a routine Schedule 13G-type reporting of a sub-5% passive stake. Key facts are the exact share count (803,487), the 4.1% ownership and the statement that holdings are in the ordinary course of business and not intended to influence control. For investors this is a clear transparency event but not a control or activist signal.
TL;DR: Joint filing and Exhibit (99.2) confirm parent-subsidiary relationship and that the stake is reported by related Goldman Sachs entities.
The exhibit identifies The Goldman Sachs Group, Inc. as a parent holding company and Goldman Sachs & Co. LLC as a subsidiary broker-dealer and investment adviser, explaining why both parties appear on the Schedule. The filing explicitly states there is no group formation or intent to influence issuer control and Item 5 notes ownership is 5% or less, so governance implications are limited based on disclosed facts.